Tottenham Acquisition I Limited (“Tottenham”) (NASDAQ: TOTA, TOTAU, TOTAW, TOTAR), a special purpose acquisition company, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) for a business combination with Clene Nanomedicine, Inc. (“Clene”), a clinical-stage biopharmaceutical company developing a potential therapeutic nanocatalyst for the treatment of neurodegenerative diseases in addition to a nanotechnology based-therapy with antiviral applications.
Read the full article: Clene Nanomedicine, Inc. to Go Public through Merger with Tottenham Acquisition I Limited //
Source: https://www.prnewswire.com/news-releases/clene-nanomedicine-inc-to-go-public-through-merger-with-tottenham-acquisition-i-limited-301122655.html